The Ohio State University Wexner Medical Center, Department of Surgery, Columbus, OH, 43210, USA.
University of Texas at Arlington, Department of Kinesiology, Arlington, TX, 76109, USA.
Redox Biol. 2022 Aug;54:102357. doi: 10.1016/j.redox.2022.102357. Epub 2022 Jun 2.
Ischemic injury to the heart induces mitochondrial dysfunction due to increasing oxidative stress. MG53, also known as TRIM72, is highly expressed in striated muscle, is secreted as a myokine after exercise, and is essential for repairing damaged plasma membrane of many tissues by interacting with the membrane lipid phosphatidylserine (PS). We hypothesized MG53 could preserve mitochondrial integrity after an ischemic event by binding to the mitochondrial-specific lipid, cardiolipin (CL), for mitochondria protection to prevent mitophagy. Fluorescent imaging and Western blotting experiments showed recombinant human MG53 (rhMG53) translocated to the mitochondria after ischemic injury in vivo and in vitro. Fluorescent imaging indicated rhMG53 treatment reduced superoxide generation in ex vivo and in vitro models. Lipid-binding assay indicated MG53 binds to CL. Transfecting cardiomyocytes with the mitochondria-targeted mt-mKeima showed inhibition of mitophagy after MG53 treatment. Overall, we show that rhMG53 treatment may preserve cardiac function by preserving mitochondria in cardiomyocytes. These findings suggest MG53's interactions with mitochondria could be an attractive avenue for developing MG53 as a targeted protein therapy for cardioprotection.
缺血性心脏损伤会导致氧化应激增加,从而引起线粒体功能障碍。MG53,也称为 TRIM72,在横纹肌中高表达,运动后作为肌因子分泌,通过与膜脂质磷脂酰丝氨酸(PS)相互作用,对于修复许多组织的受损质膜是必不可少的。我们假设 MG53 可以通过与线粒体特异性脂质心磷脂(CL)结合来保护线粒体的完整性,以防止自噬。荧光成像和 Western blot 实验表明,重组人 MG53(rhMG53)在体内和体外缺血损伤后易位到线粒体。荧光成像表明 rhMG53 治疗可减少体外和体内模型中超氧化物的产生。脂质结合实验表明 MG53 与 CL 结合。用线粒体靶向 mt-mKeima 转染心肌细胞后,MG53 处理可抑制自噬。总的来说,我们表明 rhMG53 治疗可能通过在心肌细胞中保护线粒体来维持心脏功能。这些发现表明,MG53 与线粒体的相互作用可能是开发 MG53 作为靶向蛋白治疗心脏保护的有吸引力的途径。